论文部分内容阅读
目的:对6 4例糖尿病肾病(DN)患者按2 4h尿白蛋白排泄量(UAE)分为微量白蛋白尿组和大量白蛋白尿组,每组又随机分成治疗组和对照组。治疗组在控制血糖及血压的基础上口服弹性酶6个月,对照组不用弹性酶,继续控制血糖、血压,观察6个月。治疗前后分别测2 4hUAE、血脂、血糖及肾功。结果:弹性酶能明显减少早期DN患者尿白蛋白排泄量(P<0 . 0 1) ,尤其是对DN病程短于1年、尿微量白蛋白在30～2 5 0mg/ 2 4h、伴高脂血症者效果最佳,而对临床期DN效果较差。结论:弹性酶可用于早期DN的治疗。
Aims: Sixty-four patients with diabetic nephropathy (DN) were divided into microalbuminuria group and large albuminuria group according to 24 h urinary albumin excretion (UAE), and each group was randomly divided into treatment group and control group. The treatment group on the basis of controlling blood sugar and blood pressure on the basis of oral elastase for 6 months, the control group without elastase, continue to control blood sugar, blood pressure, observed for 6 months. Before and after treatment were measured 24hUAE, lipids, blood glucose and renal function. Results: Elastase could significantly reduce urinary albumin excretion in patients with early DN (P <0. 01), especially for patients with DN course of less than 1 year, urine microalbumin 30 ~ 250mg / 2 4h, with high Lipid is the best, while the clinical effect of DN is poor. Conclusion: Elastase can be used for the treatment of early DN.